Nidhi Sharma, Muhammad Salman Faisal, Qiuhong Zhao, Justin Jiang, Patrick Elder, Don M Benson, Ashley Rosko, Maria Chaudhry, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Sumithira Vasu, Samantha Jaglowski, Alice S Mims, Hannah Choe, Karilyn Larkin, Jonathan E Brammer, Sarah Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Audrey M Sigmund, Yvonne A Efebera
Allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical (haplo) donor has emerged as a suitable alternative in the absence of a matched donor. However, haplo-HCT patients have a higher risk of graft-versus-host disease (GVHD). Hence, bone marrow (BM) stem cell source and post-transplant cyclophosphamide (PTCy) have been routinely used to help mitigate this. Due to ease of collection, peripheral blood (PB) stem cells are increasingly being considered for haplo-HCT. We retrospectively analyzed 74 patients (42 BM and 32 PB) who underwent haplo-HCT at Ohio State University from 2009 to 2018...
June 27, 2021: Journal of Clinical Medicine